1. ALLA AKTIER
  2. NYHETER
  3. ALLIGATOR BIOSCIENCE

Alligator Bioscience

Nyheter Alligator Bioscience Nyheter alla bolag
Affiliate
Courtagefri handel på Nordnet till sista juni 2027! Har du inget konto på Nordnet så är det verkligen läge att skaffa ett. Just nu får nya kunder courtagefri handel till sista juni 2027. Läs mer om erbjudandet och skapa ditt konto här
Erbjudandet gäller nya kunder och omfattar handel via Nordnets app eller hemsida i nordiska aktier, ETF:er, teckningsrätter och teckningsoptioner. För fullständiga villkor se nordnet.se/jubileum. Kom ihåg att investeringar alltid innebär en risk.

Change in number of shares and votes in Alligator Bioscience AB

LHFI

During September 2023, the number of shares and votes in Alligator Bioscience AB (“Alligator”) has increased as a result of the exercise of warrants series TO 6 which were issued in connection with the rights issue of units which was resolved by the Board of Directors on 22 March 2023 and approved by the Extraordinary General Meeting held on 24 April 2023. As of 29 September 2023, the total number of outstanding shares in Alligator amounts to 658,904,140, whereof 657,954,290 are ordinary shares with one vote each and 949,850 are series C shares with 1/10 vote each. The total number of votes as of 29 September 2023 amounts to 658,049,275.

For further information, please contact:

Søren Bregenholt, CEO
E-mail: soren.bregenholt@alligatorbioscience.com
Phone: +46 (0) 46 540 82 00

LifeSci Advisors
Investor Relations
Guillaume van Renterghem
E-mail: gvanrenterghem@lifesciadvisors.com
Phone: +41 (0) 76 735 01 31

This information is information that Alligator Bioscience is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2023-09-29 08:00 CEST.

About Alligator Bioscience

Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator’s portfolio includes several promising drug candidates, with the CD40 agonist mitazalimab as its key asset. Furthermore, Alligator is co-developing ALG.APV-527 with Aptevo Therapeutics Inc., several undisclosed molecules based on its proprietary technology platform, Neo-X-Prime™, and novel drug candidates based on the RUBY™ bispecific platform with Orion Corporation. Out-licensed programs include AC101/HLX22, in Phase 2 development, by Shanghai Henlius Biotech Inc. and an undisclosed target to Biotheus Inc.

Alligator Bioscience’s shares are listed on Nasdaq Stockholm (ATORX) and is headquartered in Lund, Sweden.

For more information, please visit alligatorbioscience.com.

Attachments

Change in number of shares and votes in Alligator Bioscience AB

Datum 2023-09-29, kl 08:00
Källa MFN
Bifogade filer
Change in number of shares and votes in Alligator Bioscience AB